INTRODUCTION: The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients. METHODS: Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. RESULTS: Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average -2.8% (95% CI -3.6, -2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. CONCLUSIONS: Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. IMPLICATIONS FOR CANCER SURVIVORS: Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.
INTRODUCTION: The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancerpatients. METHODS: Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancerpatients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. RESULTS: Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average -2.8% (95% CI -3.6, -2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. CONCLUSIONS: Substantial increases in fat and declines in lean mass were observed in prostate cancerpatients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. IMPLICATIONS FOR CANCER SURVIVORS: Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.
Authors: Zhao Chen; Michael Maricic; Paul Nguyen; Frederick R Ahmann; Roberta Bruhn; Bruce L Dalkin Journal: Cancer Date: 2002-11-15 Impact factor: 6.860
Authors: P Iversen; C J Tyrrell; A V Kaisary; J B Anderson; L Baert; T Tammela; M Chamberlain; K Carroll; K Gotting-Smith; G R Blackledge Journal: Urology Date: 1998-03 Impact factor: 2.649
Authors: J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: William A See; Manfred P Wirth; David G McLeod; Peter Iversen; Ira Klimberg; Donald Gleason; Gerald Chodak; James Montie; Chris Tyrrell; D M A Wallace; Karl P J Delaere; Sigmund Vaage; Teuvo L J Tammela; Olavi Lukkarinen; Bo-Eric Persson; Kevin Carroll; Geert J C M Kolvenbag Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: C J Tyrrell; A V Kaisary; P Iversen; J B Anderson; L Baert; T Tammela; M Chamberlain; A Webster; G Blackledge Journal: Eur Urol Date: 1998 Impact factor: 20.096
Authors: Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright Journal: Endocrine Date: 2013-10-31 Impact factor: 3.633
Authors: Chunliu Pan; Neha Jaiswal Agrawal; Yanni Zulia; Shalini Singh; Kai Sha; James L Mohler; Kevin H Eng; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk Journal: JCI Insight Date: 2020-03-26
Authors: Kim Edmunds; Haitham Tuffaha; Daniel A Galvão; Paul Scuffham; Robert U Newton Journal: Support Care Cancer Date: 2020-01-07 Impact factor: 3.603
Authors: Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2012-10-04 Impact factor: 4.104
Authors: Roisin F O'Neill; Farhana Haseen; Liam J Murray; Joe M O'Sullivan; Marie M Cantwell Journal: J Cancer Surviv Date: 2015-04-28 Impact factor: 4.442
Authors: Chunliu Pan; Shalini Singh; Deepak M Sahasrabudhe; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk Journal: Endocrinology Date: 2016-09-09 Impact factor: 4.736
Authors: Kerri M Winters-Stone; Jessica C Dobek; Jill A Bennett; Nathan F Dieckmann; Gianni F Maddalozzo; Christopher W Ryan; Tomasz M Beer Journal: Arch Phys Med Rehabil Date: 2014-09-03 Impact factor: 3.966